This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Microcap Article: Archive
Blue Dolphin Q2 Loss Narrows Y/Y, Stock Price Decreases 18%
by Zacks Equity Research
BDCO Q2 loss narrows y/y and improved margins, but revenues fell and shares drop 18% as market pressures weighed on investor sentiment.
BDCOPositive Net Change
earnings energy oil-energy
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth
by Zacks Equity Research
Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.
ELTPPositive Net Change
earnings medical
Vaso Stock Down Following Q2 Earnings as Revenue and Margins Fall
by Zacks Equity Research
VASO reports a second-quarter 2025 loss as lower imaging deliveries and rising costs pressured revenue and profit margins.
VASOPositive Net Change
earnings medical medical-devices
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
by Zacks Equity Research
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
BIAFNegative Net Change
earnings medical medical-devices
SIFCO Stock Up on Robust Q3 Earnings Recovery and Margin Expansion
by Zacks Equity Research
SIF returns to profitability in third-quarter fiscal 2025 as strong aerospace demand and cost cuts lifted margins and earnings.
SIFPositive Net Change
aerospace defense earnings
Retractable Technologies Stock Gains Following Q2 Earnings Growth
by Zacks Equity Research
RVP reports stronger second-quarter 2025 sales and narrows losses as domestic output offsets tariff headwinds.
RVPNegative Net Change
earnings medical medical-devices
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
by Zacks Equity Research
ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.
ICCCNegative Net Change
earnings medical
ClearOne Stock Falls on Wider Q2 Loss, Revenue Decline and Sale Plan
by Zacks Equity Research
CLRO posts a wider Q2 loss on revenue decline, rising costs and supply issues as it pursues an asset sale to address ongoing risks.
CLRONegative Net Change
earnings tech-stocks
Onfolio Q2 Revenues Soar 83% but Losses Persist, Shares Drop
by Zacks Equity Research
ONFO's Q2 revenues jump 83% with narrower losses, but shares tumble as investors weigh new ventures, cost cuts and the path to profitability.
ONFOPositive Net Change
earnings retail
DJCO June-Quarter Earnings Rise Y/Y on Tech Growth, Stock Up 1%
by Zacks Equity Research
Daily Journal's June-quarter earnings decrease year over year on lower investment gains and higher costs, partly offset by strong software revenues.
DJCOPositive Net Change
consumer-staples earnings